Tag: Nursing

Procedure Description: a repeat uterine ultrasound in real time with image documentation of a 32-week pregnant female with twins.What CPT codes and Modifier should be reported?

If a client with a compound fracture of the left ankle is being discharged with a below-the-knee cast, which instructions should the PN provide to the client prior to discharge?

Naloxone would be indicated for the treatment of an overdose for which of the following medications? Select all that apply.
Cocaine.
Morphine.
Fentanyl.
Diazepam.
Midazolam.
Methadone.

Mia still has chest pain and Fentanyl and Aspirin are ordered by the doctor for Mia. What is the reason these medications are prescribed, and, by what route would they be given?

High-grade fever, productive cough withpurulent sputum, crackles uponauscultation, and pleuritic pain suggests:
Influenza
Pneumonia
Tuberculosis
Upper respiratory infection
Not saved

hich of the following factors is exclusive to antineoplastic medication orders?A. Route of administrationB. Rate of administrationC. Time limitationD. Dose of the medication

ICU NURSE 100 ASSESSMENT#2
Where is Carlos’s wound located? SELECT ONE OF THE FOLLOWING (1 PT)
Right Upper Flank
Lower Right Abdomen
Left Anterior Leg
Right Forearm

objective: Launch a program to help people quit smoking, with the goal of enrolling 100 people in the first year.list the activities to do and resources needed to achieve this.
Proposed activities
Define program scope and model
Decide service mix: group counseling, one-on-one counseling, pharmacotherapy, digital support (apps, SMS), and follow-up schedule.
Set eligibility criteria and enrollment process.
Develop curriculum and materials
Create session plans, handouts, consent forms, intake questionnaires, and patient education materials.
Staffing and training
Hire or assign program manager, counselors/therapists, nurse/pharmacist support, outreach coordinator, and data officer.
Provide evidence-based cessation training (motivational interviewing, pharmacotherapy guidelines, relapse prevention).
Partnerships and referrals
Establish referral pathways with primary care clinics, hospitals, pharmacies, employers, community centers, and public health agencies.
Recruitment and outreach
Develop a marketing plan (social media, local radio, posters, flyers, community events, email campaigns, clinician referrals).
Target high-yield venues and demographics and run outreach drives to meet enrollment targets.
Enrollment and baseline assessment
Streamline intake, collect baseline smoking history, readiness to quit, and consent.
Deliver interventions
Provide scheduled counseling sessions, prescribe or supply nicotine replacement therapy (NRT) or other medications as indicated, and offer digital support between visits.
Follow-up and retention
Implement reminder systems, check-ins at key intervals (1, 3, 6, 12 months), and offer incentives for continued participation where appropriate.
Monitoring, evaluation, and quality improvement
Track enrollment, quit rates (e.g., 7-day point prevalence at 3 and 6 months), retention, and participant satisfaction. Use data to iterate on outreach and service delivery.
Scale and sustainability planning
Assess resource utilization, secure ongoing funding or billing pathways, and expand partnerships if targets are met.
Resources needed
Personnel
Program manager/coordinator
Trained counselors/behavioral therapists
Clinical support (nurse or pharmacist for medication management)
Outreach/marketing coordinator
Data manager / evaluator
Training and content
Evidence-based training courses and facilitator guides
Printed and digital educational materials for participants
Clinical supplies and medications
Nicotine replacement therapy (patches, gum, lozenges) and access to prescription cessation medications when indicated
Facilities and platforms
Physical meeting space for in-person sessions or a subscription to a secure telehealth/video conferencing platform
Phone/SMS platform for reminders and support
Marketing and outreach budget
Funds for ads, printed materials, community events, and partner engagement
Data systems and evaluation tools
Secure database or EHR integration for intake, tracking, and reporting
Survey tools for participant feedback and outcome measurement
Incentives and participant support
Small incentives (e.g., transit vouchers, gift cards) to improve recruitment and retention
Partnerships and referral agreements
MOUs with clinics, employers, pharmacies, and community organizations
Budget for evaluation and continuous improvement
Resources for periodic program reviews, data analysis, and adjustments
Targets, timeline, and key metrics
Enrollment target: 100 people in year 1 (≈9 people per month).
Retention metric: target ≥70% retention through primary intervention period (e.g., 3 months).
Quit outcomes: track 7-day point prevalence quit rates at 3 and 6 months; set interim targets (e.g., 20–40% short-term quit rate depending on intervention intensity).
Process timeline: 1–2 months for planning and hiring, months 3–12 for active recruitment and service delivery, ongoing evaluation.

Drug name (and genertic name, trade name) Dosages it comes in (include ratio calculations)Ways of administration Side effects and any other information! Of cefazolin ( Ancef )
Drug name
Generic name: cefazolin sodium
Common trade names: Ancef, Kefzol (and other regional brands)
Dosages it comes in (include ratio calculations)
Common vial strengths (powder for injection): 250 mg, 500 mg, 1 g (1000 mg), 2 g (2000 mg).
Basic conversions: 1 g = 1000 mg; 2 g = 2000 mg.
Example ratio/calculation (concentration after dilution):
1 g diluted in 50 mL → 1000 mg / 50 mL = 20 mg/mL.
1 g diluted in 100 mL → 1000 mg / 100 mL = 10 mg/mL.
2 g diluted in 100 mL → 2000 mg / 100 mL = 20 mg/mL.
500 mg diluted in 10 mL → 500 mg / 10 mL = 50 mg/mL.
Typical dosing ranges (general summaries, not patient-specific orders):
Adult infections: commonly 1–2 g IV every 8 hours depending on severity and indication.
Surgical prophylaxis: commonly 1–2 g IV as a single dose before incision (dose may be repeated for prolonged procedures or significant blood loss).
Pediatrics: commonly 25–50 mg/kg per dose IV every 8 hours (dose and interval vary by age and infection).
Renal impairment: dose and/or interval adjustments required (consult dosing references).
Ways of administration
Intravenous (IV) bolus or IV infusion (most common in hospital settings).
Intramuscular (IM) injection (less commonly used; can be painful).
Prepared as powder for reconstitution according to manufacturer instructions; then diluted in compatible IV fluids for infusion when indicated.
Not given orally—only parenteral formulations are available.
Side effects
Hypersensitivity reactions: rash, urticaria, anaphylaxis (cross-reactivity possible in some patients with penicillin allergy).
Gastrointestinal: diarrhea, nausea, vomiting; Clostridioides difficile–associated diarrhea is a potential serious complication.
Local reactions: pain or phlebitis at injection site (especially with IM or IV administration).
Hematologic: eosinophilia, neutropenia, thrombocytopenia (usually reversible).
Hepatic: transient elevations in liver enzymes.
Renal: rare nephrotoxicity; dose adjustments required in renal impairment to reduce risk of accumulation and CNS toxicity.
CNS: seizures reported rarely with very high doses or renal failure.
Other important information
Class and mechanism: first-generation cephalosporin antibiotic; bactericidal via inhibition of bacterial cell wall synthesis. Good activity against many gram-positive organisms (including MSSA and streptococci) and some gram-negative bacilli (e.g., E. coli, Proteus, Klebsiella).
Common clinical uses: surgical prophylaxis, skin and soft tissue infections, bone and joint infections, urinary tract infections (when susceptible), and bacteremia due to susceptible organisms.
Contraindications and precautions: known severe hypersensitivity to cefazolin or other cephalosporins; use caution in patients with a history of penicillin allergy. Adjust dosing in renal impairment and monitor renal function during prolonged therapy.
Pregnancy and lactation: commonly used in pregnancy when indicated; discuss with provider. Cefazolin is generally considered acceptable in pregnancy but follow local guidance.
Interactions and compatibility: check IV compatibility charts before mixing with other drugs/solutions; follow manufacturer guidance for reconstitution and diluent choice.
Monitoring: monitor for clinical response, signs of allergic reaction, C. difficile–related diarrhea, renal function, and complete blood count for prolonged therapy.
Storage and preparation: store and reconstitute per manufacturer labeling; use aseptic technique and discard unused reconstituted solution per guidance.

Moving from Disease Prevention to Health Promotion on the Wellness Continuumrequires which of the following?a) abstinenceb) Medical carec) stress free lifed) healthy choices